Moderna, Inc. (MRNA)

NASDAQ:
MRNA
| Latest update: Oct 15, 2025, 6:38 PM

Stock events for Moderna, Inc. (MRNA)

Over the past six months, Moderna's stock price has experienced fluctuations, with a 6-month return of +13.46% as of October 5, 2025. However, the share price as of October 3, 2025, was $28.48, representing a decline of 53.36% from $61.07 on October 3, 2024, and the 1-year return as of October 5, 2025, was -52.67%. In the first quarter of 2025, Moderna reported continued losses and declining sales of its COVID-19 vaccines, leading to plans for expanded cost efficiency and prioritization programs. Moderna's next earnings date is anticipated on November 6, 2025.

Demand Seasonality affecting Moderna, Inc.’s stock price

Demand for Moderna's COVID-19 vaccine is expected to be seasonal, with sales concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine transitions into a seasonal respiratory product. The company's first-quarter 2025 earnings also reflected the seasonality of its respiratory products. This seasonality is a key factor in Moderna's revenue projections, with a significant portion of its expected 2025 revenue anticipated in the latter half of the year.

Overview of Moderna, Inc.’s business

Moderna, Inc. is an American biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's core business revolves around its mRNA therapeutics platform, which develops and produces human proteins, antibodies, and novel proteins to prevent, treat, and cure diseases. Moderna's major commercial products include the Moderna COVID-19 vaccine, marketed as Spikevax, and the respiratory syncytial virus (RSV) vaccine, marketed as mRESVIA. The company also has a robust pipeline of vaccine and therapeutic candidates in various stages of development, including vaccines for seasonal influenza, cytomegalovirus (CMV), and an individualized neoantigen therapy for oncology.

MRNA’s Geographic footprint

Moderna is headquartered in Cambridge, Massachusetts, U.S., with manufacturing units in Canada, the U.S., the UK, and Australia. The company has established subsidiaries in Japan, South Korea, and Australia, and plans to expand its commercial network across Asia. In September 2025, Moderna opened its Innovation and Technology Centre (MITC) in Oxfordshire, UK, which is the UK's first facility to manufacture mRNA vaccines onshore, with the capacity to produce up to 100 million mRNA vaccine doses annually, potentially increasing to 250 million during a pandemic.

MRNA Corporate Image Assessment

Moderna has generally enjoyed a stellar reputation, particularly due to its pioneering role in developing one of the first COVID-19 vaccines. However, the company has also faced challenges that could impact its brand, including patent disputes and scrutiny over executive stock sales. Moderna opened its Innovation and Technology Centre in the UK in September 2025, reaffirming its commitment to Britain and its strategic partnership with the UK government.

Ownership

Moderna's stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion, with approximately 60.17%, 75.08%, or 75.33% of the company's stock, depending on the reporting source. Insiders own around 7.74%, and public companies and individual investors hold the remaining shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Baillie Gifford & Co, Fmr Llc, State Street Corp, Geode Capital Management, Llc, and Morgan Stanley.

Expert AI

Show me the sentiment for Moderna, Inc.
What's the latest sentiment for Moderna, Inc.?

Price Chart

$26.25

9.92%
(1 month)

Top Shareholders

The Vanguard Group, Inc.
10.82%
BlackRock, Inc.
7.42%
Baillie Gifford & Co.
5.73%
FMR LLC
5.09%
State Street Corp.
4.48%
Geode Holdings Trust
2.30%
Morgan Stanley
2.10%
Theleme Services Ltd.
2.04%
Two Sigma Advisers LP
2.03%
D. E. Shaw & Co. LP
1.93%
Invesco Ltd.
1.84%
UBS Group AG
1.81%
Two Sigma Investments LP
1.80%
Flagship Pioneering, Inc.
1.20%
Pictet & Partners
1.18%
Jane Street Group LLC
0.98%
Government of Norway
0.91%
Voloridge Holdings LP
0.88%
The Goldman Sachs Group, Inc.
0.88%
Northern Trust Corp.
0.80%

Trade Ideas for MRNA

Today

Sentiment for MRNA

News
Social

Buzz Talk for MRNA

Today

Social Media

FAQ

What is the current stock price of Moderna, Inc.?

As of the latest update, Moderna, Inc.'s stock is trading at $26.25 per share.

What’s happening with Moderna, Inc. stock today?

Today, Moderna, Inc. stock is up by 9.92%, possibly due to news.

What is the market sentiment around Moderna, Inc. stock?

Current sentiment around Moderna, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Moderna, Inc.'s stock price growing?

Over the past month, Moderna, Inc.'s stock price has increased by 9.92%.

How can I buy Moderna, Inc. stock?

You can buy Moderna, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol MRNA

Who are the major shareholders of Moderna, Inc. stock?

Major shareholders of Moderna, Inc. include institutions such as The Vanguard Group, Inc. (10.82%), BlackRock, Inc. (7.42%), Baillie Gifford & Co. (5.73%) ... , according to the latest filings.